research

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

Authors
Publication date
1 January 2018
Publisher
Digital Commons@Becker

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Digital Commons@Becker

    redirect
    oaioai:digitalcommons.wustl.edu:o...
    Last time updated on 19/10/2019